Cite
FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.
MLA
Young, Guy, et al. “FondaKIDS: A Prospective Pharmacokinetic and Safety Study of Fondaparinux in Children between 1 and 18 Years of Age.” Pediatric Blood & Cancer, vol. 57, no. 6, Dec. 2011, pp. 1049–54. EBSCOhost, https://doi.org/10.1002/pbc.23011.
APA
Young, G., Yee, D. L., O’Brien, S. H., Khanna, R., Barbour, A., & Nugent, D. J. (2011). FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatric Blood & Cancer, 57(6), 1049–1054. https://doi.org/10.1002/pbc.23011
Chicago
Young, Guy, Donald L. Yee, Sarah H. O’Brien, Rachna Khanna, April Barbour, and Diane J. Nugent. 2011. “FondaKIDS: A Prospective Pharmacokinetic and Safety Study of Fondaparinux in Children between 1 and 18 Years of Age.” Pediatric Blood & Cancer 57 (6): 1049–54. doi:10.1002/pbc.23011.